S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10

Abattis Bioceuticals Stock Forecast, Price & News

0.00 (0.00 %)
(As of 10/22/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume777,732 shs
Average Volume679,122 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ATTBF News and Ratings via Email

Sign-up to receive the latest news and ratings for Abattis Bioceuticals and its competitors with MarketBeat's FREE daily newsletter.

Abattis Bioceuticals logo

About Abattis Bioceuticals

Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cannabis industry. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.


See More Headlines

Industry, Sector and Symbol

Current Symbol
Year Founded

Sales & Book Value

Annual Sales





Next Earnings Date
Not Optionable


Overall MarketRank

0.75 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Abattis Bioceuticals (OTCMKTS:ATTBF) Frequently Asked Questions

What stocks does MarketBeat like better than Abattis Bioceuticals?

Wall Street analysts have given Abattis Bioceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Abattis Bioceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Abattis Bioceuticals' stock price been impacted by COVID-19?

Abattis Bioceuticals' stock was trading at $0.0077 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ATTBF shares have decreased by 87.0% and is now trading at $0.0010.
View which stocks have been most impacted by COVID-19

Who are Abattis Bioceuticals' key executives?

Abattis Bioceuticals' management team includes the following people:
  • Mr. Robert J. Abenante, Pres, CEO & Director (Age 38, Pay $308.67k)
  • Mr. Douglas J. Sorocco LLB, Advisor (Age 50, Pay $101.49k)
  • Mr. Guy P. Dancosse CRIA, Q.C., ICD.D, CIRC, Advisor (Age 77, Pay $119.81k)
  • Mr. Francesco Paolini, CFO & Director
  • Mr. Patrick Mitchell, COO & Director
  • Mr. Shawn Balaghi, Head of Corp. Devel.
  • Mr. Clayton Chessa, Head of Operations
  • Mr. Jim Carter, Head of Mergers and Acquisitions Advisory
  • Mr. Christopher P. Cherry CPA, CA, CGA, Corp. Comptroller (Age 42)
  • Ms. Nicole Breitinger, Corp. Sec.

What is Abattis Bioceuticals' stock symbol?

Abattis Bioceuticals trades on the OTCMKTS under the ticker symbol "ATTBF."

How do I buy shares of Abattis Bioceuticals?

Shares of ATTBF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Abattis Bioceuticals' stock price today?

One share of ATTBF stock can currently be purchased for approximately $0.00.

What is Abattis Bioceuticals' official website?

The official website for Abattis Bioceuticals is www.abattis.com.

Where are Abattis Bioceuticals' headquarters?

Abattis Bioceuticals is headquartered at 625 Howe Street, Vancouver, BC V6C.

This page was last updated on 10/24/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.